Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Bachem Holding AG
  6. News
  7. Summary
    BANB   CH0012530207

BACHEM HOLDING AG

(BANB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bachem : Will Targeting Alpha-Synuclein Lead to Treatments for Parkinson's Disease?

05/25/2021 | 09:01am EDT

α-Synuclein is the principal constituent of the main neuropathological characteristic of Parkinson's disease. α-Synuclein is a protein that is abundant in neurons and localized in vicinity to presynaptic terminals. As a matter of fact, α-synuclein aggregates and forms insoluble fibrils in the dopaminergic neurons, which causes dysfunction in the release of neurotransmitters, critical for the normal brain function.

Thus, α-synuclein has emerged as a major target in Parkinson's disease and other related conditions known as synucleinopathies. Researchers have been studying the role of α-synuclein to determine how this protein may influence Parkinson's disease and Lewy body dementia (LBD). LBD encompasses the two related clinical diagnoses of Parkinson's disease dementia and dementia with Lewy bodies1What is LBD? Lewy Body Dementia Association 2019. Among candidates in the drug development pipeline, there are several different approaches for α-synuclein targeted therapeutics including reducing extracellular α-synuclein, blocking the misfolding of α-synuclein, preventing α-synuclein aggregation, and curtailing α-synuclein synthesis. α-Synuclein exists in several structural forms and researchers have identified that reducing the formation and propagation of β-sheet oligomers could be a route for therapeutic intervention2J.M. Froula et al. J. Bio. Chem., 294, 10392-10406 (2019). Several drug candidates targeting α-synuclein are known to be in the early stages of drug development from preclinical to Phase II as shown in Figure 1.
Figure 1 Estimated Number of alpha-Synuclein Targeted Drug Candidates by Development Stage (Source: GlobalData)
The current pipeline of α-synuclein targeted therapies consists of small molecules, antibodies, proteins and peptides, antisense oligonucleotides, and gene therapies. To achieve reduction of extracellular α-synuclein, passive therapies such as the administration of prepared antibodies and active immunization using synthetic peptides are under development. Examples of clinical programs include NPT200-11, a small molecule inhibitor of α-synuclein misfolding, ANVS-401 (Posiphen), an inhibitor of α-synuclein synthesis, and ENT-01, a small molecule drug candidate that prevents the aggregation of α-synuclein by stabilizing conformations of α-synuclein that are incapable of assembling into toxic pore-like oligomers in cell membranes3GlobalData 2021.

Parkinson's disease results from a complex combination of genetic and environmental factors. Yet their respective influence on the disease initiation could likely vary from one individual to another. Consequently, therapeutic strategies for preventing or slowing disease progression might be more efficient, if personalized to each case. With our strong expertise and leading position as peptides manufacturer, we offer a large selection of peptides, amino acid derivatives, and biochemicals. Our innovative peptides portfolio includes a variety of sequence modifications, and salt forms, as well as established bioactive peptides used in different applications such as Parkinson's disease and multiple sclerosis research.

At Bachem, we support pharmaceutical companies in their development of new oligonucleotide and peptide modalities for new therapeutic applications. For companies and organizations needing a manufacturer of active pharmaceutical ingredients (APIs), we offer the production of New Chemical Entities including both peptides and oligonucleotides. Our technological leadership and innovative strength have been the cornerstones of our success since the very beginning of our company. We look forward to working with our partners to bring medical advances and new oligonucleotide-based treatments to patients worldwide.

Disclaimer

Bachem Holding AG published this content on 25 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2021 13:00:04 UTC.


ę Publicnow 2021
All news about BACHEM HOLDING AG
06/17BACHEMá : Mirabaud Securities Lifts Price Target on Bachem, Maintains Buy Recomm..
MT
06/15BACHEMá : A world market leader from the Basel region – Bachem celebrates ..
PU
06/14BACHEMá : What are Amino Acids?
PU
06/10BACHEMá : Antimicrobial Peptides
PU
06/08BACHEMá : recognized as a winner at the Swiss Biotech Success Stories Awards 202..
PU
06/04BACHEMá : What is GMP?
PU
05/27BACHEMá : Amyloid Beta Peptides & Alzheimer's Disease
PU
05/27PRESS RELEASE : Santhera Publishes Agenda for its Annual General Meeting
DJ
05/25BACHEMá : Will Targeting Alpha-Synuclein Lead to Treatments for Parkinson's Dise..
PU
05/11MEET BACHEM : Swetlana Meinhardt, Category Manager
PU
More news
Financials
Sales 2021 481 M 522 M 522 M
Net income 2021 102 M 111 M 111 M
Net Debt 2021 151 M 164 M 164 M
P/E ratio 2021 72,5x
Yield 2021 0,66%
Capitalization 7 404 M 8 062 M 8 043 M
EV / Sales 2021 15,7x
EV / Sales 2022 13,3x
Nbr of Employees 1 475
Free-Float 42,9%
Chart BACHEM HOLDING AG
Duration : Period :
Bachem Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BACHEM HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 501,67 CHF
Last Close Price 529,00 CHF
Spread / Highest target 13,4%
Spread / Average Target -5,17%
Spread / Lowest Target -25,3%
EPS Revisions
Managers and Directors
NameTitle
Thomas Meier Chief Executive Officer
Alain Schaffter Chief Financial Officer
Kuno Sommer Chairman
GŘnther Loidl Chief Technology Officer
Ralph Sch÷nleber Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BACHEM HOLDING AG33.75%8 062
MODERNA, INC.99.33%83 614
LONZA GROUP AG13.26%52 103
IQVIA HOLDINGS INC.35.88%46 660
CELLTRION, INC.-24.79%33 793
SEAGEN INC.-9.62%28 728